Aerovate Therapeutics Inc... (AVTE)
2.47
-0.03 (-1.20%)
At close: Jan 14, 2025, 3:59 PM
2.43
-1.62%
After-hours Jan 14, 2025, 07:49 PM EST
undefined% (undefined)
| Bid | 2.24 |
| Market Cap | 71.32M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.99 |
| PE Ratio (ttm) | -0.83 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.61 |
| Volume | 605,787 |
| Avg. Volume (20D) | 800,431 |
| Open | 2.51 |
| Previous Close | 2.50 |
| Day's Range | 2.43 - 2.51 |
| 52-Week Range | 1.25 - 32.41 |
| Beta | undefined |
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 51
Stock Exchange NASDAQ
Ticker Symbol AVTE
Website https://aerovatetx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $2, which is a decrease of -19.03% from the latest price.
Buy 14.29%
Hold 85.71%
Sell 0.00%
2 months ago ·
Source
+11.87%
Aerovate Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
6 months ago ·
Source
+8.07%
Aerovate Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.
